A Novel Use of Romiplostim for SARS-CoV-2–induced Thrombocytopenia
| Autor: | Scott W Penney, Coursen W Schneider, Alison M Helfrich, Kip R. Hartman, Kenneth Lieuw |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty Romiplostim business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Eltrombopag Hematology Disease medicine.disease medicine.disease_cause Thrombocytopenic purpura chemistry.chemical_compound Immune system Oncology chemistry Pediatrics Perinatology and Child Health medicine Platelet Pediatrics Perinatology and Child Health business medicine.drug Coronavirus |
| Zdroj: | Journal of Pediatric Hematology/Oncology |
| ISSN: | 1077-4114 |
| DOI: | 10.1097/mph.0000000000001961 |
| Popis: | The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|